A detailed history of Great West Life Assurance CO transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 6,276 shares of RCKT stock, worth $143,218. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,276
Previous 6,276 -0.0%
Holding current value
$143,218
Previous $187,000 9.63%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$16.78 - $31.94 $21,629 - $41,170
1,289 Added 25.85%
6,276 $187,000
Q3 2023

Nov 14, 2023

BUY
$15.07 - $24.05 $50,755 - $81,000
3,368 Added 208.03%
4,987 $102,000
Q2 2023

Aug 10, 2023

SELL
$16.59 - $23.6 $21,600 - $30,727
-1,302 Reduced 44.57%
1,619 $32,000
Q4 2022

Feb 10, 2023

BUY
$15.5 - $22.76 $6,618 - $9,718
427 Added 17.12%
2,921 $57,000
Q3 2022

Nov 01, 2022

BUY
$12.37 - $18.41 $30,850 - $45,914
2,494 New
2,494 $40,000
Q2 2022

Aug 09, 2022

BUY
$7.96 - $16.64 $859 - $1,797
108 Added 4.76%
2,377 $32,000
Q1 2022

May 12, 2022

BUY
$13.16 - $23.68 $1,473 - $2,652
112 Added 5.19%
2,269 $39,000
Q4 2021

Feb 14, 2022

BUY
$21.52 - $36.02 $2,259 - $3,782
105 Added 5.12%
2,157 $47,000
Q3 2020

Nov 17, 2020

BUY
$20.5 - $28.59 $9,266 - $12,922
452 Added 28.25%
2,052 $46,000
Q3 2020

Nov 13, 2020

SELL
$20.5 - $28.59 $9,266 - $12,922
-452 Reduced 22.03%
1,600 $36,000
Q4 2019

Feb 11, 2020

BUY
$11.07 - $24.23 $22,715 - $49,719
2,052 New
2,052 $46,000
Q3 2019

Oct 25, 2019

SELL
$10.85 - $14.78 $41,967 - $57,169
-3,868 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$14.58 - $23.0 $56,395 - $88,964
3,868 New
3,868 $76,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $1.73B
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.